Home / NEWS & DEALS / Deals / details of junhe's deals

JunHe Assists Zylox-Tonbridge in its IPO and Listing on the Hong Kong Stock Exchange

2021.07.05

On July 5, 2021, Zylox-Tonbridge Medical Technology Co., Ltd. ( hereinafter referred to as " Zylox-Tonbridge " or "the company") issued 60,000,000 H-shares worldwide (excluding the over allotment part) and was listed on the main board of the Hong Kong Stock Exchange, at a rate of HK$ 42.7 per share. The IPO of the company was popular in the market, with more than 1,190 times oversubscribed, and the fund-raising scale (before exercising the over allotment right) exceeded HK$ 2.56 billion.

 

Zylox-Tonbridge is a leading player in the neuro and peripheral vascular interventional medical device market in China. Since its establishment in 2012, the company has developed a portfolio of 45 products and candidate products in the nerve and peripheral vascular device market. Zylox-Tonbridge’s current therapeutic areas include acute ischemic stroke, intracranial aneurysm, carotid artery stenosis, peripheral arterial and venous diseases and dialysis related diseases. It is the only domestic company in the field of neurovascular interventional medical devices to develop a full range of products for the major neurovascular categories, i.e. ischemic, hemorrhagic, stenosis, carotid and vascular access devices. It has a leading position in the diversity of its product portfolio and product approvals in the area of peripheral vascular interventional medical devices in China.

 

JunHe acted as the Chinese legal adviser to the co-sponsors and underwriters of this project. The team’s outstanding, rigorous and efficient legal services overcame the adverse effects of the epidemic and other unfavorable factors. They assisted the underwriters in legal due diligence, reviewed and modified the prospectus, and assisted in preparing the application of the listing documents submitted to the CSRC and the Hong Kong Stock Exchange. JunHe’s team also issued Chinese legal opinions and assisted in replying to the relevant legal issues in China of concern by the China Securities Regulatory Commission and the Hong Kong Stock Exchange. The JunHe team's working attitude and professional service ability won praise and unanimous affirmation from its clients and the other intermediaries.

 

This project was led by Partners Mr. SHAO, Chunyang and Mr. JIANG, Wenjun (Kelvin)

JunHe is the only Chinese law firm to be admitted as a member of Lex Mundi and Multilaw, two international networks of independent law firms. JunHe and selected top law firms in major European and Asian jurisdictions are “best friends.” Through these connections, we provide high quality legal services to clients doing business throughout the world.